Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02960646 · ClinicalTrials.gov registry record · Phase 1
Engineered Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies
A Phase 1 study, sponsored by M.D. Anderson Cancer Center.
- Completed
- Registry status
- Phase 1
- Development phase
- 11
- Enrollment target
NCT02960646: Completed Phase 1 study, sponsored by M.D. Anderson Cancer Center.
NCT02960646 is a Phase 1 study that has completed, run by M.D. Anderson Cancer Center. The registered enrollment target is 11 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02960646, a Phase 1 study, has completed, sponsored by M.D. Anderson Cancer Center.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 11 participants
- Enrollment target
Study Summary
This pilot phase I trial studies the side effects of engineered donor stem cell transplant in treating patients with hematologic malignancies. Sometimes the transplanted cells from a donor can make an immune response against the body's normal cells (called graft-versus-host disease). Using T cells specially selected from donor blood in the laboratory for transplant may stop this from happening.
Interventions
- DRUG Cyclophosphamide
- DRUG Melphalan
- OTHER Laboratory Biomarker Analysis
- BIOLOGICAL Filgrastim
- DRUG Fludarabine Phosphate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 11 participants |
| Start Date | 2017-01-18 |
| Est. Completion | 2023-02-13 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02960646
The ClinicalTrials.gov registry entry for NCT02960646 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 11 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Cyclophosphamide is the first listed.
NCT02960646 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02960646 about?
NCT02960646 is a clinical study titled "Engineered Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies". This pilot phase I trial studies the side effects of engineered donor stem cell transplant in treating patients with hematologic malignancies. Sometimes the transplanted cells from a donor can make an immune response against the body's normal cells (called graft-versus-host disease). Using T cells s...
What is the current status of trial NCT02960646?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 11 participants. The study started on 2017-01-18. Estimated completion is 2023-02-13.
What interventions are being tested in trial NCT02960646?
The interventions under investigation include: Cyclophosphamide (DRUG), Melphalan (DRUG), Laboratory Biomarker Analysis (OTHER), Filgrastim (BIOLOGICAL), Fludarabine Phosphate (DRUG).
Who is sponsoring clinical trial NCT02960646?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.